These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
447 related articles for article (PubMed ID: 19562639)
21. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Romaguera JE; Fayad LE; Feng L; Hartig K; Weaver P; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak L; Wang M Br J Haematol; 2010 Jul; 150(2):200-8. PubMed ID: 20528872 [TBL] [Abstract][Full Text] [Related]
22. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858 [TBL] [Abstract][Full Text] [Related]
23. Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. Hill BT; Rybicki L; Smith S; Dean R; Kalaycio M; Pohlman B; Sweetenham J; Tench S; Sobecks R; Andresen S; Copelan E; Bolwell BJ Leuk Lymphoma; 2011 Jun; 52(6):986-93. PubMed ID: 21314484 [TBL] [Abstract][Full Text] [Related]
24. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Chen RW; Li H; Bernstein SH; Kahwash S; Rimsza LM; Forman SJ; Constine L; Shea TC; Cashen AF; Blum KA; Fenske TS; Barr PM; Phillips T; Leblanc M; Fisher RI; Cheson BD; Smith SM; Faham M; Wilkins J; Leonard JP; Kahl BS; Friedberg JW Br J Haematol; 2017 Mar; 176(5):759-769. PubMed ID: 27992063 [TBL] [Abstract][Full Text] [Related]
25. High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. Lossos IS; Hosein PJ; Morgensztern D; Coleman F; Escalón MP; Byrne GE; Rosenblatt JD; Walker GR Leuk Lymphoma; 2010 Mar; 51(3):406-14. PubMed ID: 20038221 [TBL] [Abstract][Full Text] [Related]
26. [Therapy of mantle cell lymphoma]. Udvardy M Orv Hetil; 2009 Dec; 150(50):2253-7. PubMed ID: 19951856 [TBL] [Abstract][Full Text] [Related]
27. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299 [TBL] [Abstract][Full Text] [Related]
28. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127 [TBL] [Abstract][Full Text] [Related]
29. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Lefrère F; Delmer A; Suzan F; Levy V; Belanger C; Djabarri M; Arnulf B; Damaj G; Maillard N; Ribrag V; Janvier M; Sebban C; Casasnovas RO; Bouabdallah R; Dreyfus F; Verkarre V; Delabesse E; Valensi F; McIntyre E; Brousse N; Varet B; Hermine O Leukemia; 2002 Apr; 16(4):587-93. PubMed ID: 11960337 [TBL] [Abstract][Full Text] [Related]
30. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation. Qiao W; Zhao J; Wang C; Wang T; Xing Y Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658 [TBL] [Abstract][Full Text] [Related]
31. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208 [TBL] [Abstract][Full Text] [Related]
32. Validation of the Mantle Cell Lymphoma International Prognostic Index: A single-center retrospective analysis. Smith SD; Hsi E; Bolwell B; Pohlman B; Dean R; Effinger M; Maggiotto A; Sweetenham J Am J Hematol; 2010 Jun; 85(6):454-6. PubMed ID: 20513126 [TBL] [Abstract][Full Text] [Related]
33. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Martin P; Chadburn A; Christos P; Furman R; Ruan J; Joyce MA; Fusco E; Glynn P; Elstrom R; Niesvizky R; Feldman EJ; Shore TB; Schuster MW; Ely S; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP Ann Oncol; 2008 Jul; 19(7):1327-1330. PubMed ID: 18349031 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Cairoli R; Grillo G; Tedeschi A; Gargantini L; Marenco P; Tresoldi E; Barbarano L; Nosari AM; Morra E Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265 [TBL] [Abstract][Full Text] [Related]
35. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved? Dreyling M; Hiddemann W Curr Opin Oncol; 2008 Sep; 20(5):487-94. PubMed ID: 19106649 [TBL] [Abstract][Full Text] [Related]
36. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. Hermine O; Jiang L; Walewski J; Bosly A; Thieblemont C; Szymczyk M; Pott C; Salles G; Feugier P; Hübel K; Haioun C; Casasnovas RO; Schmidt C; Bouabdallah K; Ribrag V; Kanz L; Dürig J; Metzner B; Sibon D; Cheminant M; Burroni B; Klapper W; Hiddemann W; Unterhalt M; Hoster E; Dreyling M; J Clin Oncol; 2023 Jan; 41(3):479-484. PubMed ID: 36469833 [No Abstract] [Full Text] [Related]
37. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab]. Kanaji N; Ishibashi K; Uno H; Hino N Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485 [TBL] [Abstract][Full Text] [Related]
38. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Lefrère F; Delmer A; Levy V; Delarue R; Varet B; Hermine O Haematologica; 2004 Oct; 89(10):1275-6. PubMed ID: 15477221 [TBL] [Abstract][Full Text] [Related]
39. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Ludwig WD; Dörken B; Freund M; Huber C; Ganser A; Trümper L; Forstpointner R; Unterhalt M; Hiddemann W Ann Oncol; 2007 Jan; 18(1):136-142. PubMed ID: 17071931 [TBL] [Abstract][Full Text] [Related]
40. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]